LiCl and SB216763, both inhibitors of the serine/threonine glycogen synthase kinase 3β (GSK3β), were antiproliferative against Jurkat (acute T-cell leukemia), K562 (CML), and RPMI-8226 (myeloma) cells by promotion of proteasomal MYB degradation and suppression of BCL2, survivin, and MYC. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.